{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:18:52Z","timestamp":1794745132677,"version":"4.9.1"},"reference-count":178,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006013","name":"United Arab Emirates University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.biopha.2026.119894","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:19:03Z","timestamp":1790086743000},"page":"119894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Bridging the gap between experimental evidence and clinical applications of antipseudomonal phage therapy against Pseudomonas aeruginosa"],"prefix":"10.1016","volume":"204","author":[{"given":"Ahmed","family":"Elfadadny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wedad M.","family":"Nageeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rokaia F.","family":"Ragab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazim O.","family":"Khalifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119894_bib1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1099\/mic.0.000860","article-title":"Microbe profile: Pseudomonas aeruginosa: Opportunistic pathogen and lab rat","volume":"166","author":"Diggle","year":"2020","journal-title":"Microbiol. (U. Kingd. )"},{"key":"10.1016\/j.biopha.2026.119894_bib2","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00138-18","article-title":"Cystic fibrosis and pseudomonas aeruginosa: the host-microbe interface","volume":"32","author":"Malhotra","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.biopha.2026.119894_bib3","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/QCO.0000000000000717","article-title":"Skin manifestations of Pseudomonas aeruginosa infections","volume":"34","author":"Spernovasilis","year":"2021","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.biopha.2026.119894_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2023.1074127","article-title":"Antimicrobial resistance and genotyping of Pseudomonas aeruginosa isolated from the ear canals of dogs in Japan","volume":"10","author":"Elfadadny","year":"2023","journal-title":"Front. Vet. Sci."},{"key":"10.1016\/j.biopha.2026.119894_bib5","first-page":"1231","article-title":"Pseudomonas otitis externa in dogs","volume":"59","author":"Pye","year":"2018","journal-title":"Can. Vet. J."},{"key":"10.1016\/j.biopha.2026.119894_bib6","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1365-3164.2006.00550.x","article-title":"Pyoderma caused by Pseudomonas aeruginosa infection in dogs: 20 Cases","volume":"17","author":"Hillier","year":"2006","journal-title":"Vet. Dermatol."},{"key":"10.1016\/j.biopha.2026.119894_bib7","article-title":"Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016\/429): antimicrobial-resistant Pseudomonas aeruginosa in dogs and cats","volume":"20","author":"Nielsen","year":"2022","journal-title":"EFSA J."},{"key":"10.1016\/j.biopha.2026.119894_bib8","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.biopha.2026.119894_bib9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.drup.2015.08.002","article-title":"The increasing threat of Pseudomonas aeruginosa high-risk clones","volume":"21\u201322","author":"Oliver","year":"2015","journal-title":"Drug. Resist. Updat."},{"key":"10.1016\/j.biopha.2026.119894_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00031-19","article-title":"Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections","volume":"32","author":"Horcajada","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.biopha.2026.119894_bib11","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.gendis.2019.04.001","article-title":"Emergence of antibiotic resistance Pseudomonas aeruginosa in intensive care unit; a critical review","volume":"6","author":"Pachori","year":"2019","journal-title":"Genes. Dis."},{"key":"10.1016\/j.biopha.2026.119894_bib12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/microbiolres13010002","article-title":"The history and applications of phage therapy in pseudomonas aeruginosa","volume":"13","author":"Silva","year":"2021","journal-title":"Microbiol. Res. (Pavia)"},{"key":"10.1016\/j.biopha.2026.119894_bib13","doi-asserted-by":"crossref","first-page":"R55","DOI":"10.1186\/cc10026","article-title":"Pseudomonas aeruginosa acquisition on an intensive care unit: relationship between antibiotic selective pressure and patients\u2019 environment","volume":"15","author":"Boyer","year":"2011","journal-title":"Crit. Care"},{"key":"10.1016\/j.biopha.2026.119894_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2024.1374466","article-title":"Antimicrobial resistance of Pseudomonas aeruginosa: navigating clinical impacts, current resistance trends, and innovations in breaking therapies","volume":"15","author":"Elfadadny","year":"2024","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.biopha.2026.119894_bib15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.tim.2011.04.005","article-title":"Pseudomonas aeruginosa: all roads lead to resistance","volume":"19","author":"Breidenstein","year":"2011","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.biopha.2026.119894_bib16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrmicro3380","article-title":"Molecular mechanisms of antibiotic resistance","volume":"13","author":"Blair","year":"2015","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.biopha.2026.119894_bib17","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1128\/AAC.00148-07","article-title":"Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation","volume":"51","author":"Henrichfreise","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2026.119894_bib18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biotechadv.2018.11.013","article-title":"Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies","volume":"37","author":"Pang","year":"2019","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.biopha.2026.119894_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01999-19","article-title":"Multidrug adaptive resistance of Pseudomonas aeruginosa swarming cells","volume":"64","author":"Coleman","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2026.119894_bib20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/978-4-431-55120-1_8","article-title":"One health: from concept to practice","author":"Mackenzie","year":"2014","journal-title":"Confronting Emerg. Zoonoses One Heal. Paradig."},{"key":"10.1016\/j.biopha.2026.119894_bib21","doi-asserted-by":"crossref","first-page":"19393","DOI":"10.1038\/s41598-021-98457-z","article-title":"Isolation and characterization of a lytic bacteriophage against Pseudomonas aeruginosa","volume":"11","author":"Sharma","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119894_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2020.556706","article-title":"Temperate Bacteriophages (Prophages) in Pseudomonas aeruginosa Isolates Belonging to the International Cystic Fibrosis Clone (CC274","volume":"11","author":"Ambroa","year":"2020","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.biopha.2026.119894_bib23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/icb.1960.34","article-title":"Lysogeny in Pseudomonas aeruginosa","volume":"38","author":"Holloway","year":"1960","journal-title":"Aust. J. Exp. Biol. Med. Sci."},{"key":"10.1016\/j.biopha.2026.119894_bib24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s00705-022-05694-2","article-title":"Abolishment of morphology-based taxa and change to binomial species names: 2022 taxonomy update of the ICTV bacterial viruses subcommittee","volume":"168","author":"Turner","year":"2023","journal-title":"Arch. Virol."},{"key":"10.1016\/j.biopha.2026.119894_bib25","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0769-2617(88)80075-3","article-title":"Morphology of Pseudomonas aeruginosa typing phages of the lindberg set","volume":"139","author":"Ackermann","year":"1988","journal-title":"Ann. l\u2019Inst. Pasteur Virol."},{"key":"10.1016\/j.biopha.2026.119894_bib26","doi-asserted-by":"crossref","first-page":"7449","DOI":"10.1128\/JVI.00385-15","article-title":"Phage therapy: a step forward in the treatment of pseudomonas aeruginosa infections","volume":"89","author":"Pires","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2026.119894_bib27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-1-60327-164-6_13","article-title":"Phage classification and characterization","volume":"501","author":"Ackermann","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.biopha.2026.119894_bib28","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3390\/amh69030016","article-title":"Exploring bacteriophage applications in medicine and beyond","volume":"69","author":"Elfadadny","year":"2024","journal-title":"Acta Microbiol. Hell."},{"key":"10.1016\/j.biopha.2026.119894_bib29","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1128\/AAC.04641-14","article-title":"Novel phage Lysin capable of killing the multidrug-resistant gram-negative bacterium Acinetobacter Baumannii in a mouse bacteremia model","volume":"59","author":"Lood","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2026.119894_bib30","series-title":"A literature review of the practical application of bacteriophage research","author":"Chanishvili","year":"2012"},{"key":"10.1016\/j.biopha.2026.119894_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-017-1709-y","article-title":"Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury-a case report","volume":"21","author":"Jennes","year":"2017","journal-title":"Crit. Care"},{"key":"10.1016\/j.biopha.2026.119894_bib32","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.virol.2013.05.022","article-title":"Safety analysis of a Russian phage cocktail: from MetaGenomic analysis to oral application in healthy human subjects","volume":"443","author":"McCallin","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.biopha.2026.119894_bib33","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ebiom.2015.12.023","article-title":"Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh","volume":"4","author":"Sarker","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.biopha.2026.119894_bib34","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1128\/AAC.49.7.2874-2878.2005","article-title":"Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy","volume":"49","author":"Bruttin","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2026.119894_bib35","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.micres.2018.04.007","article-title":"Biotechnological applications of bacteriophages: state of the art","volume":"212\u2013213","author":"Harada","year":"2018","journal-title":"Microbiol. Res."},{"key":"10.1016\/j.biopha.2026.119894_bib36","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.tim.2015.01.006","article-title":"Revisiting phage therapy: new applications for old resources","volume":"23","author":"Nobrega","year":"2015","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.biopha.2026.119894_bib37","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1128\/MMBR.00069-15","article-title":"Genetically engineered phages: a review of advances over the last decade","volume":"80","author":"Pires","year":"2016","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.biopha.2026.119894_bib38","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1128\/AAC.48.10.3817-3822.2004","article-title":"Therapy of experimental Pseudomonas infections with a nonreplicating genetically modified phage","volume":"48","author":"Hagens","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2026.119894_bib39","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3390\/ph8030525","article-title":"Ecology of anti-biofilm agents I: antibiotics versus bacteriophages","volume":"8","author":"Abedon","year":"2015","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.biopha.2026.119894_bib40","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.2147\/IDR.S367460","article-title":"Assessment of phage-mediated inhibition and removal of multidrug-resistant pseudomonas aeruginosa biofilm on medical implants","volume":"15","author":"Amankwah","year":"2022","journal-title":"Infect. Drug. Resist."},{"key":"10.1016\/j.biopha.2026.119894_bib41","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1128\/AAC.00669-09","article-title":"Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system","volume":"54","author":"Fu","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2026.119894_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12866-021-02197-z","article-title":"Sewage and sewage-contaminated environments are the most prominent sources to isolate phages against Pseudomonas aeruginosa","volume":"21","author":"Aghaee","year":"2021","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.biopha.2026.119894_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01330","article-title":"Use of a primary epithelial cell screening tool to investigate phage therapy in cystic fibrosis","volume":"9","author":"Trend","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119894_bib44","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00284-009-9417-8","article-title":"Isolation of Pseudomonas aeruginosa specific phages with broad activity spectra","volume":"59","author":"Knezevic","year":"2009","journal-title":"Curr. Microbiol."},{"key":"10.1016\/j.biopha.2026.119894_bib45","doi-asserted-by":"crossref","first-page":"12265","DOI":"10.1038\/s41598-018-30705-1","article-title":"Novel phages of healthy skin metaviromes from South Africa","volume":"8","author":"van Zyl","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119894_bib46","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/1743-422X-7-346","article-title":"Hepatitis C virus, human immunodeficiency virus and pseudomonas phage PS5 triad share epitopes of immunogenic determinants","volume":"7","author":"Golkar","year":"2010","journal-title":"Virol. J."},{"key":"10.1016\/j.biopha.2026.119894_bib47","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature04160","article-title":"Viruses in the sea","volume":"437","author":"Suttle","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119894_bib48","doi-asserted-by":"crossref","first-page":"e01215","DOI":"10.1128\/mSphere.01215-20","article-title":"A Novel N4-like bacteriophage isolated from a wastewater source in south india with activity against several multidrug-resistant clinical pseudomonas aeruginosa isolates","volume":"6","author":"Menon","year":"2021","journal-title":"MSphere"},{"key":"10.1016\/j.biopha.2026.119894_bib49","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.biologicals.2015.05.004","article-title":"Sewage as a rich source of phage study against Pseudomonas aeruginosa PAO","volume":"43","author":"Azizian","year":"2015","journal-title":"Biologicals"},{"key":"10.1016\/j.biopha.2026.119894_bib50","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-1-60327-164-6_7","article-title":"Enumeration of bacteriophages by double agar overlay plaque assay","volume":"501","author":"Kropinski","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.biopha.2026.119894_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120200","article-title":"Phage cocktail powder for Pseudomonas aeruginosa respiratory infections","volume":"596","author":"Li","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119894_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics10070877","article-title":"Pseudomonas aeruginosa pao 1 in vitro time\u2013kill kinetics using single phages and phage formulations\u2014modulating death, adaptation, and resistance","volume":"10","author":"Pinto","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.biopha.2026.119894_bib53","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01652-19","article-title":"Resistance evolution against phage combinations depends on the timing and order of exposure","volume":"10","author":"Wright","year":"2019","journal-title":"MBio"},{"key":"10.1016\/j.biopha.2026.119894_bib54","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1128\/AEM.66.4.1416-1422.2000","article-title":"Isolation of bacteriophages specific to a fish pathogen, Pseudomonas plecoglossicida, as a candidate for disease control","volume":"66","author":"Park","year":"2000","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.biopha.2026.119894_bib55","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02573-17","article-title":"Design of a broad-range bacteriophage cocktail that reduces pseudomonas aeruginosa biofilms and treats acute infections in two animal models","volume":"62","author":"Forti","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2026.119894_bib56","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3389\/fmicb.2020.00327","article-title":"Development of a bacteriophage cocktail to constrain the emergence of phage-resistant pseudomonas aeruginosa","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.biopha.2026.119894_bib57","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/emph\/eoaa026","article-title":"Phage steering of antibiotic-resistance evolution in the bacterial pathogen, Pseudomonas aeruginosa","volume":"2020","author":"Gurney","year":"2020","journal-title":"Evol. Med. Public. Heal."},{"key":"10.1016\/j.biopha.2026.119894_bib58","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.copbio.2020.10.002","article-title":"Unlocking the next generation of phage therapy: the key is in the receptors","volume":"68","author":"Gordillo Altamirano","year":"2021","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.biopha.2026.119894_bib59","doi-asserted-by":"crossref","first-page":"26717","DOI":"10.1038\/srep26717","article-title":"Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa","volume":"6","author":"Chan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119894_bib60","article-title":"Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance","volume":"72","author":"WHO, WHO bacterial priority pathogens list","year":"2024"},{"key":"10.1016\/j.biopha.2026.119894_bib61","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cmi.2020.04.039","article-title":"Pharmacokinetics\/pharmacodynamics of antipseudomonal bacteriophage therapy in rats: a proof-of-concept study","volume":"26","author":"Lin","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.biopha.2026.119894_bib62","article-title":"Pharmacokinetics and time-kill study of inhaled antipseudomonal bacteriophage therapy in mice","volume":"65","author":"Chow","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2026.119894_bib63","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/2042098612469335","article-title":"The ABCD of clinical pharmacokinetics","volume":"4","author":"Doogue","year":"2013","journal-title":"Ther. Adv. Drug. Saf."},{"key":"10.1016\/j.biopha.2026.119894_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics10040421","article-title":"Phage therapy in veterinary medicine","volume":"10","author":"Loponte","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.biopha.2026.119894_bib65","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/1534734619835115","article-title":"Bacteriophage therapy of chronic nonhealing wound: clinical study","volume":"18","author":"Gupta","year":"2019","journal-title":"Int. J. Low. Extrem. Wounds"},{"key":"10.1016\/j.biopha.2026.119894_bib66","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1007\/s10096-012-1691-x","article-title":"Phage therapy to control multidrug-resistant Pseudomonas aeruginosa skin infections: In vitro and ex vivo experiments","volume":"31","author":"Vieira","year":"2012","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.biopha.2026.119894_bib67","doi-asserted-by":"crossref","first-page":"360","DOI":"10.4103\/0377-4929.42511","article-title":"Utility of lytic bacteriophage in the treatment of multidrug-resistant Pseudomonas aeruginosa septicemia in mice","volume":"51","author":"Vinodkumar","year":"2008","journal-title":"Indian. J. Pathol. Microbiol."},{"key":"10.1016\/j.biopha.2026.119894_bib68","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1128\/AAC.01028-06","article-title":"Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model","volume":"51","author":"McVay","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2026.119894_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2020.198250","article-title":"A single dose of a virulent bacteriophage vB PaeP-SaPL, rescues bacteremic mice infected with multi drug resistant Pseudomonas aeruginosa","volume":"292","author":"Alvi","year":"2021","journal-title":"Virus Res."},{"key":"10.1016\/j.biopha.2026.119894_bib70","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2174\/138920110790725401","article-title":"Phage therapy in clinical practice: treatment of human infections","volume":"11","author":"Kutter","year":"2010","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.biopha.2026.119894_bib71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047742","article-title":"Pseudomonas aeruginosa keratitis in mice: effects of topical bacteriophage KPP12 administration","volume":"7","author":"Fukuda","year":"2012","journal-title":"PLoS. One"},{"key":"10.1016\/j.biopha.2026.119894_bib72","first-page":"563","article-title":"Studies on bacteriophage penetration in patients subjected to phage therapy","volume":"35","author":"Weber-Dabrowska","year":"1987","journal-title":"Arch. Immunol. Ther. Exp. (Warsz. )"},{"key":"10.1016\/j.biopha.2026.119894_bib73","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a023879","article-title":"Phage therapy in the era of synthetic biology","volume":"8","author":"Barbu","year":"2016","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.biopha.2026.119894_bib74","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/med.21572","article-title":"Phage therapy: What factors shape phage pharmacokinetics and bioavailability? Systematic and critical review","volume":"39","author":"D\u0105browska","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.biopha.2026.119894_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2018.00376","article-title":"Bacteriophage therapy: clinical trials and regulatory hurdles","volume":"8","author":"Furfaro","year":"2018","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.biopha.2026.119894_bib76","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00003088-200342040-00002","article-title":"Pharmacokinetic principles of bacteriophage therapy","volume":"42","author":"Payne","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.biopha.2026.119894_bib77","doi-asserted-by":"crossref","first-page":"279","DOI":"10.4172\/1747-0862.1000050","article-title":"The role of regulated clinical trials in the development of bacteriophage therapeutics","volume":"06","author":"Parracho","year":"2012","journal-title":"J. Mol. Genet. Med."},{"key":"10.1016\/j.biopha.2026.119894_bib78","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/jobm.201500764","article-title":"A virulent phage JHP against Pseudomonas aeruginosa showed infectivity against multiple genera","volume":"56","author":"Khawaja","year":"2016","journal-title":"J. Basic. Microbiol."},{"key":"10.1016\/j.biopha.2026.119894_bib79","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.lfs.2017.09.034","article-title":"Isolation and characterization of a bacteriophage and its utilization against multi-drug resistant Pseudomonas aeruginosa-2995","volume":"190","author":"Jamal","year":"2017","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2026.119894_bib80","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1089\/jamp.2014.1172","article-title":"Bacteriophage delivery by nebulization and efficacy against phenotypically diverse pseudomonas aeruginosa from cystic fibrosis patients","volume":"28","author":"Sahota","year":"2015","journal-title":"J. Aerosol Med. Pulm. Drug. Deliv."},{"key":"10.1016\/j.biopha.2026.119894_bib81","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1365-2672.2010.04863.x","article-title":"vitro lung delivery of bacteriophages KS4-M and \u03a6KZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis","volume":"110","author":"Golshahi","year":"2011","journal-title":"J. Appl. Microbiol."},{"key":"10.1016\/j.biopha.2026.119894_bib82","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1365-2672.2009.04469.x","article-title":"Bacteriophage-derived enzyme that depolymerizes the alginic acid capsule associated with cystic fibrosis isolates of Pseudomonas aeruginosa","volume":"108","author":"Glonti","year":"2010","journal-title":"J. Appl. Microbiol."},{"key":"10.1016\/j.biopha.2026.119894_bib83","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.resmic.2011.06.010","article-title":"Use of newly isolated phages for control of Pseudomonas aeruginosa PAO1 and ATCC 10145 biofilms","volume":"162","author":"Pires","year":"2011","journal-title":"Res. Microbiol."},{"key":"10.1016\/j.biopha.2026.119894_bib84","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1038\/ncomms5780","article-title":"Pseudomonas aeruginosa adaptation in the nasopharyngeal reservoir leads to migration and persistence in the lungs","volume":"5","author":"Fothergill","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119894_bib85","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijpharm.2019.01.050","article-title":"Storage stability of inhalable phage powders containing lactose at ambient conditions","volume":"560","author":"Chang","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119894_bib86","doi-asserted-by":"crossref","first-page":"8572","DOI":"10.1038\/s41467-024-52595-w","article-title":"Targeting Pseudomonas aeruginosa biofilm with an evolutionary trained bacteriophage cocktail exploiting phage resistance trade-offs","volume":"15","author":"Kunisch","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119894_bib87","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/s41598-018-37636-x","article-title":"Phage therapy against Pseudomonas aeruginosa infections in a cystic fibrosis zebrafish model","volume":"9","author":"Cafora","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119894_bib88","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/infdis\/jiy678","article-title":"Bacteriophage therapy increases complement-mediated lysis of bacteria and enhances bacterial clearance after acute lung infection with multidrug-resistant pseudomonas aeruginosa","volume":"219","author":"Abd El-Aziz","year":"2019","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.biopha.2026.119894_bib89","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ijantimicag.2015.04.005","article-title":"Assessing phage therapy against Pseudomonas aeruginosa using a Galleria mellonella infection model","volume":"46","author":"Beeton","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.biopha.2026.119894_bib90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016963","article-title":"Pulmonary bacteriophage therapy on pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention","volume":"6","author":"Morello","year":"2011","journal-title":"PLoS. One"},{"key":"10.1016\/j.biopha.2026.119894_bib91","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00029-12","article-title":"Bacteriophages \u03c6MR299-2 and \u03c6NH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells","volume":"3","author":"Alemayehu","year":"2012","journal-title":"MBio"},{"key":"10.1016\/j.biopha.2026.119894_bib92","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1086\/651135","article-title":"Bacteriophages can treat and prevent pseudomonas aeruginosa lung infections","volume":"201","author":"Debarbieux","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.biopha.2026.119894_bib93","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1136\/thoraxjnl-2016-209265","article-title":"Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa","volume":"72","author":"Waters","year":"2017","journal-title":"Thorax"},{"key":"10.1016\/j.biopha.2026.119894_bib94","article-title":"Pharmacokinetics and time-kill study of inhaled antipseudomonal bacteriophage therapy in mice","volume":"65","author":"Chow","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2026.119894_bib95","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075380","article-title":"Pseudomonas aeruginosa adaptation to lungs of cystic fibrosis patients leads to lowered resistance to phage and protist enemies","volume":"8","author":"Friman","year":"2013","journal-title":"PLoS. One"},{"key":"10.1016\/j.biopha.2026.119894_bib96","first-page":"703","article-title":"Synergistic interaction between phage therapy and antibiotics clears Pseudomonas Aeruginosa infection in endocarditis and reduces virulence","volume":"215","author":"Oechslin","year":"2017","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.biopha.2026.119894_bib97","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.1128\/AEM.01166-16","article-title":"Phage therapy is effective in a mouse model of bacterial equine keratitis","volume":"82","author":"Furusawa","year":"2016","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.biopha.2026.119894_bib98","first-page":"668","article-title":"Phages, fitness, virulence, and synergy: a novel approach for the therapy of infections caused by Pseudomonas aeruginosa","volume":"215","author":"Stratton","year":"2017","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.biopha.2026.119894_bib99","doi-asserted-by":"crossref","first-page":"28115","DOI":"10.1038\/srep28115","article-title":"A proposed integrated approach for the preclinical evaluation of phage therapy in Pseudomonas infections","volume":"6","author":"Danis-Wlodarczyk","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119894_bib100","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01714-17","article-title":"Proof-of-principle study in a murine lung infection model of antipseudomonal activity of phage PEV20 in a dry-powder formulation","volume":"62","author":"Chang","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2026.119894_bib101","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/1746-6148-9-264","article-title":"Novel bacteriophage therapy for controlling metallo-beta-lactamase producing Pseudomonas aeruginosa infection in Catfish","volume":"9","author":"Khairnar","year":"2013","journal-title":"BMC Vet. Res."},{"key":"10.1016\/j.biopha.2026.119894_bib102","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.chom.2017.06.018","article-title":"Synergy between the host immune system and bacteriophage is essential for successful phage therapy against an acute respiratory pathogen","volume":"22","author":"Roach","year":"2017","journal-title":"Cell. Host Microbe"},{"key":"10.1016\/j.biopha.2026.119894_bib103","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1007\/s12275-011-1512-4","article-title":"Antibacterial efficacy of lytic Pseudomonas bacteriophage in normal and neutropenic mice models","volume":"49","author":"Tiwari","year":"2011","journal-title":"J. Microbiol."},{"key":"10.1016\/j.biopha.2026.119894_bib104","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1128\/AAC.01646-08","article-title":"Antibacterial efficacy of phages against Pseudomonas aeruginosa infections in mice and Drosophila melanogaster","volume":"53","author":"Heo","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2026.119894_bib105","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1128\/AAC.00635-06","article-title":"Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice","volume":"51","author":"Watanabe","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2026.119894_bib106","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1111\/bph.15526","article-title":"Inhaled bacteriophage therapy in a porcine model of pneumonia caused by Pseudomonas aeruginosa during mechanical ventilation","volume":"178","author":"Guillon","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119894_bib107","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.rvsc.2021.04.010","article-title":"Efficacy assessment of PEV2 phage on Galleria mellonella larvae infected with a Pseudomonas aeruginosa dog otitis isolate","volume":"136","author":"Antoine","year":"2021","journal-title":"Res. Vet. Sci."},{"key":"10.1016\/j.biopha.2026.119894_bib108","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.cmi.2022.01.006","article-title":"The effects of different doses of inhaled bacteriophage therapy for Pseudomonas aeruginosa pulmonary infections in mice","volume":"28","author":"Chang","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.biopha.2026.119894_bib109","doi-asserted-by":"crossref","DOI":"10.1128\/AEM.02900-18","article-title":"Two novel bacteriophages improve survival in Galleria mellonella infection and mouse acute pneumonia models infected with extensively drug-resistant Pseudomonas aeruginosa","volume":"85","author":"Jeon","year":"2019","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.biopha.2026.119894_bib110","first-page":"309","article-title":"Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa","volume":"17","author":"Wang","year":"2006","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.biopha.2026.119894_bib111","first-page":"16","article-title":"An in vivo wound model utilizing bacteriophage therapy of pseudomonas aeruginosa biofilms","volume":"61","author":"Basu","year":"2015","journal-title":"Ostomy Wound Manag."},{"key":"10.1016\/j.biopha.2026.119894_bib112","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.3390\/v7082835","article-title":"Phage \u03a6Pan70, a putative temperate phage, controls pseudomonas aeruginosa in planktonic, biofilm and burn mouse model assays","volume":"7","author":"Holgu\u00edn","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2026.119894_bib113","article-title":"Phage vB_PaeS-PAJD-1 Rescues Murine Mastitis Infected With Multidrug-Resistant Pseudomonas aeruginosa","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.biopha.2026.119894_bib114","doi-asserted-by":"crossref","first-page":"237","DOI":"10.12968\/jowc.2009.18.6.42801","article-title":"Bacteriophage therapy of venous leg ulcers in humans: Results of a phase i safety trial","volume":"18","author":"Rhoads","year":"2009","journal-title":"J. Wound Care"},{"key":"10.1016\/j.biopha.2026.119894_bib115","first-page":"1","article-title":"Bacteriophage therapy in clinical practice: case studies of Pseudomonas aeruginosa infections","author":"Elfadadny","year":"2025","journal-title":"J. Chemother."},{"key":"10.1016\/j.biopha.2026.119894_bib116","first-page":"66","article-title":"Experimental phage therapy of burn wound infection: difficult first steps","volume":"4","author":"Rose","year":"2014","journal-title":"Int. J. Burns Trauma."},{"key":"10.1016\/j.biopha.2026.119894_bib117","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.vetmic.2010.05.014","article-title":"Topical treatment of Pseudomonas aeruginosa otitis of dogs with a bacteriophage mixture: a before\/after clinical trial","volume":"146","author":"Hawkins","year":"2010","journal-title":"Vet. Microbiol."},{"key":"10.1016\/j.biopha.2026.119894_bib118","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0305-4179(94)90184-8","article-title":"Bacteriophage prevents destruction of skin grafts by Pseudomonas aeruginosa","volume":"20","author":"Soothill","year":"1994","journal-title":"Burns"},{"key":"10.1016\/j.biopha.2026.119894_bib119","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1473-3099(18)30482-1","article-title":"Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1\/2 trial","volume":"19","author":"Jault","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.biopha.2026.119894_bib120","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1749-4486.2009.01973.x","article-title":"A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; A preliminary report of efficacy","volume":"34","author":"Wright","year":"2009","journal-title":"Clin. Otolaryngol."},{"key":"10.1016\/j.biopha.2026.119894_bib121","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216292","article-title":"Fast phage detection and quantification: an optical density-based approach","volume":"14","author":"Rajnovic","year":"2019","journal-title":"PLoS. One"},{"key":"10.1016\/j.biopha.2026.119894_bib122","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/978-1-60327-164-6_14","article-title":"Phage host range and efficiency of plating","volume":"501","author":"Kutter","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.biopha.2026.119894_bib123","doi-asserted-by":"crossref","DOI":"10.1093\/femsre\/fuab040","article-title":"Recent progress toward the implementation of phage therapy in Western medicine","volume":"46","author":"Pirnay","year":"2022","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.biopha.2026.119894_bib124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.d4436","article-title":"European Commission bans Egyptian seeds over E coli fears","volume":"343","author":"Tuffs","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.biopha.2026.119894_bib125","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.burns.2006.02.012","article-title":"Multiplication of therapeutically administered bacteriophages in Pseudomonas aeruginosa infected patients","volume":"32","author":"Marza","year":"2006","journal-title":"Burns"},{"key":"10.1016\/j.biopha.2026.119894_bib126","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1046\/j.1365-4362.2002.01451.x","article-title":"A novel sustained-release matrix based on biodegradable poly(ester amide)s and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds","volume":"41","author":"Markoishvili","year":"2002","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.biopha.2026.119894_bib127","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1529-1049(01)00015-0","article-title":"Bacteriophage therapy for infections in cancer patients","volume":"1","author":"Weber-Dabrowska","year":"2001","journal-title":"Clin. Appl. Immunol. Rev."},{"key":"10.1016\/j.biopha.2026.119894_bib128","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s15010-019-01319-0","article-title":"Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient","volume":"47","author":"Law","year":"2019","journal-title":"Infection"},{"key":"10.1016\/j.biopha.2026.119894_bib129","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/emph\/eoy005","article-title":"Phage treatment of an aortic graft infected with Pseudomonas aeruginosa","volume":"2018","author":"Chan","year":"2018","journal-title":"Evol. Med. Public. Heal."},{"key":"10.1016\/j.biopha.2026.119894_bib130","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1164\/rccm.201904-0839LE","article-title":"Bacteriophage therapy of ventilator-associated pneumonia and empyema caused by pseudomonas aeruginosa","volume":"200","author":"Maddocks","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.biopha.2026.119894_bib131","article-title":"Bacteriophages as adjuvant to antibiotics for the treatment of periprosthetic joint infection caused by multidrug-resistant pseudomonas aeruginosa","volume":"64","author":"Tkhilaishvili","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2026.119894_bib132","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.medmal.2008.06.023","article-title":"Phage therapy experience at the Eliava Institute","volume":"38","author":"Kutateladze","year":"2008","journal-title":"Med. Mal. Infect."},{"key":"10.1016\/j.biopha.2026.119894_bib133","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics9050232","article-title":"Bacteriophage therapy for critical infections related to cardiothoracic surgery","volume":"9","author":"Rubalskii","year":"2020","journal-title":"Antibiotics"},{"key":"10.1016\/j.biopha.2026.119894_bib134","doi-asserted-by":"crossref","DOI":"10.3390\/v13101901","article-title":"Phage therapy experience at the eliava phage therapy center: three cases of bacterial persistence","volume":"13","author":"Zaldastanishvili","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2026.119894_bib135","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/jpids\/pix056","article-title":"Refractory pseudomonas bacteremia in a 2-year-old sterilized by bacteriophage therapy","volume":"7","author":"Duplessis","year":"2018","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"10.1016\/j.biopha.2026.119894_bib136","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202113936","article-title":"Bacterial lysis, autophagy and innate immune responses during adjunctive phage therapy in a child","volume":"13","author":"Khatami","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.biopha.2026.119894_bib137","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s41591-025-03678-8","article-title":"Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis","volume":"31","author":"Chan","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2026.119894_bib138","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1038\/s41467-025-60598-4","article-title":"Phage therapy with nebulized cocktail BX004-A for chronic Pseudomonas aeruginosa infections in cystic fibrosis: a randomized first-in-human trial","volume":"16","author":"Weiner","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119894_bib139","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00181-19","article-title":"Antimicrobial resistance in ESKAPE pathogens","volume":"33","author":"De Oliveira","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.biopha.2026.119894_bib140","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jhin.2026.05.008","article-title":"Epidemiology of carbapenem resistance and carbapenemase genes in Gram-negative clinical isolates from Egypt: a systematic review and meta-analysis","volume":"174","author":"Nageeb","year":"2026","journal-title":"J. Hosp. Infect."},{"key":"10.1016\/j.biopha.2026.119894_bib141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph14030184","article-title":"Synergistic killing and re-sensitization of pseudomonas aeruginosa to antibiotics by phage-antibiotic combination treatment","volume":"14","author":"Engeman","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.biopha.2026.119894_bib142","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s10068-018-0351-z","article-title":"Combined effect of bacteriophage and antibiotic on the inhibition of the development of antibiotic resistance in Salmonella typhimurium","volume":"27","author":"Petsong","year":"2018","journal-title":"Food Sci. Biotechnol."},{"key":"10.1016\/j.biopha.2026.119894_bib143","series-title":"Methods Mol Biol","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/978-1-60327-164-6_17","article-title":"Bacteriophage plaques: theory and analysis","author":"Abedon","year":"2009"},{"key":"10.1016\/j.biopha.2026.119894_bib144","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/1471-2180-11-181","article-title":"Effects of bacteriophage traits on plaque formation","volume":"11","author":"Gallet","year":"2011","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.biopha.2026.119894_bib145","doi-asserted-by":"crossref","first-page":"31909","DOI":"10.1103\/PhysRevE.69.031909","article-title":"Approximate solution to the speed of spreading viruses","volume":"69","author":"Ortega-Cejas","year":"2004","journal-title":"Phys. Rev. E - Stat. Nonlinear Soft Matter Phys."},{"key":"10.1016\/j.biopha.2026.119894_bib146","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0463.2009.02563.x","article-title":"Beta-lactam antibiotics: from antibiosis to resistance and bacteriology","volume":"118","author":"Kong","year":"2010","journal-title":"Apmis"},{"key":"10.1016\/j.biopha.2026.119894_bib147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/microorganisms9010152","article-title":"Aztreonam lysine increases the activity of phages e79 and phikz against pseudomonas aeruginosa pa01","volume":"9","author":"Davis","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.biopha.2026.119894_bib148","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ejpb.2020.11.019","article-title":"Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation-A proof-of-principle study in a P. aeruginosa lung infection model","volume":"158","author":"Lin","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.biopha.2026.119894_bib149","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1089\/mdr.2006.12.164","article-title":"Augmentation of the antimicrobial efficacy of antibiotics by filamentous phage","volume":"12","author":"Hagens","year":"2006","journal-title":"Microb. Drug. Resist."},{"key":"10.1016\/j.biopha.2026.119894_bib150","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2106\/JBJS.K.01135","article-title":"Bacteriophage therapy in implant-related infections: an experimental study","volume":"95","author":"Yilmaz","year":"2013","journal-title":"J. Bone Jt Surg."},{"key":"10.1016\/j.biopha.2026.119894_bib151","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1099\/jmm.0.029744-0","article-title":"Bacteriophage therapy for refractory Pseudomonas aeruginosa urinary tract infection","volume":"60","author":"Khawaldeh","year":"2011","journal-title":"J. Med. Microbiol."},{"key":"10.1016\/j.biopha.2026.119894_bib152","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics10080946","article-title":"Successful intratracheal treatment of phage and antibiotic combination therapy of a multi-drug resistant pseudomonas aeruginosa murine model","volume":"10","author":"Duplessis","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.biopha.2026.119894_bib153","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1111\/ajt.15503","article-title":"Early clinical experience of bacteriophage therapy in 3 lung transplant recipients","volume":"19","author":"Aslam","year":"2019","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.biopha.2026.119894_bib154","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1038\/s41467-025-59806-y","article-title":"Adjunctive phage therapy improves antibiotic treatment of ventilator-associated-pneumonia with Pseudomonas aeruginosa","volume":"16","author":"Weissfuss","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119894_bib155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/antibiotics10020145","article-title":"Pseudomonas aeruginosa resistance to bacteriophages and its prevention by strategic therapeutic cocktail formulation","volume":"10","author":"Vaitekenas","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.biopha.2026.119894_bib156","first-page":"122","article-title":"Phage therapy","volume":"43","author":"Bowater","year":"2016","journal-title":"Microbiol. Today"},{"key":"10.1016\/j.biopha.2026.119894_bib157","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrmicro2315","article-title":"Bacteriophage resistance mechanisms","volume":"8","author":"Labrie","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.biopha.2026.119894_bib158","doi-asserted-by":"crossref","first-page":"fnw002","DOI":"10.1093\/femsle\/fnw002","article-title":"Host receptors for bacteriophage adsorption","volume":"363","author":"Bertozzi Silva","year":"2016","journal-title":"FEMS Microbiol. Lett."},{"key":"10.1016\/j.biopha.2026.119894_bib159","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2174\/138920312804871193","article-title":"Learning from bacteriophages - advantages and limitations of phage and phage-encoded protein applications","volume":"13","author":"Drulis-Kawa","year":"2013","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.biopha.2026.119894_bib160","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2353\/ajpath.2007.060872","article-title":"Pathophysiology of sepsis","volume":"170","author":"Remick","year":"2007","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biopha.2026.119894_bib161","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4161\/viru.25991","article-title":"A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens","volume":"5","author":"Wittebole","year":"2014","journal-title":"Virulence"},{"key":"10.1016\/j.biopha.2026.119894_bib162","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/jam.12565","article-title":"Observation of inflammatory responses in mice orally fed with bacteriophage T7","volume":"117","author":"Park","year":"2014","journal-title":"J. Appl. Microbiol."},{"key":"10.1016\/j.biopha.2026.119894_bib163","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.resmic.2010.09.011","article-title":"Bacteriophage therapy for Staphylococcus aureus bacteremia in streptozotocin-induced diabetic mice","volume":"161","author":"Sunagar","year":"2010","journal-title":"Res. Microbiol."},{"key":"10.1016\/j.biopha.2026.119894_bib164","first-page":"766","article-title":"Bacteriophage therapy for the treatment of infections","volume":"10","author":"G\u00f3rski","year":"2009","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.biopha.2026.119894_bib165","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ejpb.2019.08.004","article-title":"Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections","volume":"142","author":"Lin","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.biopha.2026.119894_bib166","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ijpharm.2018.09.024","article-title":"Synergy of nebulized phage PEV20 and ciprofloxacin combination against Pseudomonas aeruginosa","volume":"551","author":"Lin","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119894_bib167","first-page":"186","article-title":"Efficacy of bacteriophage-antibiotic combinations against Staphylococcus aureus infection: In vitro study","volume":"30","author":"Ali","year":"2015","journal-title":"Int. J. Pharm. Sci. Rev. Res."},{"key":"10.1016\/j.biopha.2026.119894_bib168","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1111\/jam.15647","article-title":"Bacteriophage-antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa: in vitro synergy testing","volume":"133","author":"Holger","year":"2022","journal-title":"J. Appl. Microbiol."},{"key":"10.1016\/j.biopha.2026.119894_bib169","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1208\/s12248-019-0315-0","article-title":"Bacteriophage PEV20 and Ciprofloxacin Combination Treatment Enhances Removal of Pseudomonas aeruginosa Biofilm Isolated from Cystic Fibrosis and Wound Patients","volume":"21","author":"Chang","year":"2019","journal-title":"AAPS J."},{"key":"10.1016\/j.biopha.2026.119894_bib170","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nature06248","article-title":"Bacterial pathogenomics","volume":"449","author":"Pallen","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119894_bib171","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.3201\/eid1006.030472","article-title":"Bacteriophages and diffusion of \u03b2-lactamase genes","volume":"10","author":"Muniesa","year":"2004","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.biopha.2026.119894_bib172","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02071-21","article-title":"Considerations for the use of phage therapy in clinical practice","volume":"66","author":"Suh","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2026.119894_bib173","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0065-3527(08)60785-X","article-title":"Tailed bacteriophages: the order caudovirales","volume":"51","author":"Ackermann","year":"1998","journal-title":"Adv. Virus Res."},{"key":"10.1016\/j.biopha.2026.119894_bib174","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.chom.2022.01.013","article-title":"Caudovirales bacteriophages are associated with improved executive function and memory in flies, mice, and humans","volume":"30","author":"Mayneris-Perxachs","year":"2022","journal-title":"Cell. Host Microbe"},{"key":"10.1016\/j.biopha.2026.119894_bib175","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/vim.2013.0128","article-title":"Phage neutralization by sera of patients receiving phage therapy","volume":"27","author":"\u0141usiak-Szelachowska","year":"2014","journal-title":"Viral Immunol."},{"key":"10.1016\/j.biopha.2026.119894_bib176","first-page":"81","article-title":"Phage therapy: The pharmacology of antibacterial viruses","volume":"40","author":"Danis-Wlodarczyk","year":"2020","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.biopha.2026.119894_bib177","doi-asserted-by":"crossref","first-page":"5557","DOI":"10.1128\/JVI.76.11.5557-5564.2002","article-title":"Overcoming the phage replication threshold: a mathematical model with implications for phage therapy","volume":"76","author":"Kasman","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2026.119894_bib178","doi-asserted-by":"crossref","DOI":"10.1080\/21597081.2016.1220348","article-title":"Phage therapy dosing: the problem(s) with multiplicity of infection (MOI)","volume":"6","author":"Abedon","year":"2016","journal-title":"Bacteriophage"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T11:56:34Z","timestamp":1794743794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226009303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":178,"alternative-id":["S0753332226009303"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119894","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bridging the gap between experimental evidence and clinical applications of antipseudomonal phage therapy against Pseudomonas aeruginosa","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119894","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119894"}}